速递｜安进下调GLP-1药物III期研究剂量：降低剂量以限制副作用

Core Viewpoint - Amgen's experimental obesity treatment drug MariTide requires starting treatment at low doses to minimize side effects such as vomiting, leading to a nearly 6% drop in the company's stock price following the announcement of new trial results [2][5]. Group 1: Trial Results and Drug Efficacy - The ongoing 72-week Phase III trial will assign overweight or obese participants to one of three dosing regimens, starting with lower initial doses and gradually increasing over eight weeks [2]. - In a Phase II trial, MariTide helped patients lose up to 20% of their weight, with effective results observed for both monthly and bi-monthly dosing [5]. - The drug combines antibodies and two peptides targeting receptors activated by GLP-1, which suppresses appetite and regulates blood sugar, while also blocking GIP, a hormone involved in digestive functions [5]. Group 2: Side Effects and Comparisons - Nearly 90% of participants who started at the highest dose reported vomiting, while only 22% of those who gradually reached the target dose experienced the same issue [3]. - Amgen reported no new safety concerns in the trial, with side effects consistent with other GLP-1 class drugs. In comparison, Novo Nordisk's Wegovy had a vomiting rate of 24%, and Eli Lilly's Zepbound had a rate of 13% [6]. Group 3: Future Plans and Additional Benefits - Amgen plans to initiate more Phase III clinical trials this year to evaluate MariTide's effects on patients with complex health conditions, such as cardiovascular diseases and obstructive sleep apnea [7]. - The drug has shown potential to lower blood sugar levels by up to 2.2 percentage points in type 2 diabetes patients and is associated with improvements in key cardiovascular metabolic indicators, including waist circumference, blood pressure, inflammatory markers, and cholesterol levels [7].